Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesOphthalmology/OptometryAetna VEGF Inhibitors Coverage & Prior Auth | Open…
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    CurrentAetnaPolicy 0701

    Vascular Endothelial Growth Factor Inhibitors for Ocular Indications

    Customize your policy alerts

    Sign up for Aetna Policy 0701 alerts

    Get alerted when Policy 0701 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs medical necessity, precertification, and coverage criteria for vascular endothelial growth factor (VEGF) inhibitor injections for ocular indications under Aetna commercial medical plans, and identifies required prescriber specialties and continuation criteria.

    Policy Summary
    PayerAetna
    PolicyVascular Endothelial Growth Factor Inhibitors for Ocular Indications
    Policy CodePolicy 0701
    Change TypeNo material change
    Effective DateMar 15, 2005
    Last ReviewApr 22, 2027
    Next Review DateApr 22, 2027
    Key ActionPrecertification is required for listed intravitreal VEGF inhibitors and prior authorization must document the specific drug, ocular indication and dosing regimen.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    RequiredPrecertification status
    DME/AMD/RVOCommon indications
    MultipleAgents addressed
    InfectionExplicit contraindication
    OphthalmologistProvider requirement

    Coverage Criteria for Intravitreal VEGF Inhibitors

    Aflibercept (Eylea) Initial Therapy

    Aflibercept (Eylea and listed biosimilars) considered medically necessary for treatment of:

    Aflibercept initial indications: Member has one of the listed diagnoses: (1) Diabetic macular edema; (2) Diabetic retinopathy; (3) Macular edema following retinal vein occlusion; (4) Neovascular (wet) age-related macular degeneration (AMD); (5) Retinopathy of prematurity (Eylea and listed biosimilars only)

    Must be prescribed by or in consultation with an ophthalmologist.

    Aflibercept Continuation

    Continuation of aflibercept therapy is medically necessary when ALL of the following are met:

    Aflibercept continuation: Member previously approved for an indication listed in the Criteria for Initial Approval and has demonstrated a positive clinical response to therapy (e.g., improvement or maintenance in best corrected visual acuity [BCVA] or visual field, or a reduction in the rate of vision decline or the risk of more severe vision loss)
    Policy Summary
    PayerAetna
    PolicyVascular Endothelial Growth Factor Inhibitors for Ocular Indications
    Policy CodePolicy 0701
    Change TypeNo material change
    Effective DateMar 15, 2005
    Last ReviewApr 22, 2027
    Next Review DateApr 22, 2027
    Key ActionPrecertification is required for listed intravitreal VEGF inhibitors and prior authorization must document the specific drug, ocular indication and dosing regimen.
    SourceLink
    On This Page
    Coverage Criteria for Intravitreal VEGF InhibitorsBilling and Diagnosis CodesPrecertification, Prior Authorization, and Documentation RequirementsBackground and Clinical EvidenceDefinitions and Key TermsPolicy Revision History

    Bevacizumab (Avastin) Initial Therapy

    Bevacizumab (Avastin and listed biosimilars) considered medically necessary for treatment of:

    Bevacizumab initial indications: Member has one of the listed diagnoses: (1) Diabetic macular edema; (2) Neovascular (wet) age-related macular degeneration; (3) Macular edema following retinal vein occlusion; (4) Proliferative diabetic retinopathy; (5) Choroidal neovascularization (including myopic CNV, angioid streaks, ocular histoplasmosis-related CNV, idiopathic degenerative myopia, retinal dystrophies, trauma); (6) Neovascular glaucoma; (7) Retinopathy of prematurity; (8) Polypoidal choroidal vasculopathy

    Must be prescribed by or in consultation with an ophthalmologist.

    Bevacizumab (Avastin) Continuation

    Continuation of bevacizumab therapy is medically necessary when ALL of the following are met:

    Bevacizumab continuation: Member previously approved for an indication listed in the Criteria for Initial Approval and has demonstrated a positive clinical response to therapy (e.g., improvement or maintenance in best corrected visual acuity [BCVA] or visual field, or a reduction in the rate of vision decline or the risk of more severe vision loss)

    Brolucizumab (Beovu) Initial Therapy

    Brolucizumab (Beovu) considered medically necessary for treatment of:

    Brolucizumab indications: Neovascular (wet) age-related macular degeneration OR Diabetic macular edema

    Must be prescribed by or in consultation with an ophthalmologist.

    Brolucizumab Continuation

    Continuation of brolucizumab therapy is medically necessary when ALL of the following are met:

    Brolucizumab continuation: Member previously approved for an indication listed in the Criteria for Initial Approval and has demonstrated a positive clinical response to therapy (e.g., improvement or maintenance in best corrected visual acuity [BCVA] or visual field, or a reduction in the rate of vision decline or the risk of more severe vision loss)

    Intravitreal faricimab-svoa (Vabysmo) — Initial and Continuation

    Aetna considers intravitreal faricimab-svoa (Vabysmo) medically necessary for the following when prescribed by or in consultation with an ophthalmologist:

    Faricimab indications: Member has one of the listed diagnoses: Diabetic macular edema; Neovascular (wet) age-related macular degeneration; or Macular edema following retinal vein occlusion.

    All other indications are considered not medically necessary; continuation allowed with demonstrated positive clinical response (improvement or maintenance in BCVA or visual field, or reduction in rate of vision decline).

    Intravitreal ranibizumab products — Initial and Continuation

    Aetna considers intravitreal ranibizumab products medically necessary for specified retinal disorders when prescribed by or in consultation with an ophthalmologist:

    Ranibizumab indications: Ranibizumab products (Lucentis, Cimerli, Byooviz) are medically necessary for: Diabetic macular edema; Diabetic retinopathy; Macular edema following retinal vein occlusion; Myopic choroidal neovascularization; and Neovascular (wet) age-related macular degeneration.

    All other indications are considered not medically necessary; continuation allowed with demonstrated positive clinical response.

    Intravitreal ranibizumab injection (Susvimo) — Initial and Continuation

    Aetna considers intravitreal ranibizumab injection (Susvimo) and the Susvimo ocular implant medically necessary for listed indications only when ALL criteria are met:

    Susvimo for neovascular AMD: 1) Member has diagnosis of neovascular (wet) age-related macular degeneration; AND 2) Member has previously responded to at least two intravitreal injections of a VEGF inhibitor (e.g., Avastin, Eylea) within the past 6 months; AND 3) Must be used in conjunction with the Susvimo ocular implant.

    Similar all-criteria logic applies for diabetic macular edema and diabetic retinopathy indications as listed.

    Product-specific dosing and coverage

    Covered when dosing and indication align with FDA-approved prescribing information and policy statements

    Susvimo implant: Susvimo ocular implant is medically necessary when used with intravitreal ranibizumab injection for neovascular AMD, diabetic macular edema, or diabetic retinopathy and when criteria are met for intravitreal ranibizumab injection (Susvimo).

    Implant refills and procedures require aseptic technique (refill q24 weeks for nAMD/DME; q36 weeks for DR).

    Aflibercept (Eylea) dosing - nAMD: 2 mg intravitreal every 4 weeks for first 3 months, then every 8 weeks; some may need every 4 weeks after first 12 weeks; option for one dose every 12 weeks after one year in some patients; regular assessment required.2 mg

    Source: Eylea prescribing information.

    Aflibercept (Eylea) dosing - RVO: 2 mg intravitreal every 4 weeks for macular edema following RVO.2 mg every 4 weeks

    Source: Eylea prescribing information.

    Aflibercept (Eylea) dosing - DME/DR: 2 mg intravitreal every 4 weeks for first 5 injections then every 8 weeks; some may need every 4 weeks after first 20 weeks.2 mg

    Source: Eylea prescribing information.

    Aflibercept (Eylea) - ROP: 0.4 mg (0.01 mL) intravitreal; may be given bilaterally same day; injections may be repeated; interval between doses in same eye at least 10 days.0.4 mg; interval >= 10 days

    Source: Eylea ROP dosing.

    Aflibercept (Eylea HD) dosing: 8 mg intravitreal every 4 weeks for first 3 doses, then every 8 to 16 weeks; some patients may require return to every 4-week dosing if response not maintained with extended intervals.8 mg

    Source: Eylea HD prescribing information.

    Product-specific dosing (informational)

    Dosage and administration recommendations by product and indication

    Aflibercept biosimilars dosing: Aflibercept biosimilars (Enzeevu, Pavblu, Eydenzelt, Yesafili, Ahzantive, Opuviz) typically follow the aflibercept 2 mg dosing: monthly x3 then q8w for nAMD; monthly for RVO; monthly x5 then q8w for DME/DR, with clinician adjustment as needed.as described

    Manufacturer prescribing information referenced.

    Brolucizumab (Beovu) dosing: 6 mg intravitreal: for nAMD monthly x3 then q8-12w maintenance; for DME every 6 weeks for first five doses then q8-12w maintenance.6 mg; specified intervals

    Source: Novartis, 2023.

    Faricimab (Vabysmo) dosing: 6 mg intravitreal: nAMD—monthly x4 then individualized maintenance (examples: weeks 28 & 44; 24,36,48; 20,28,36,44); DME—monthly x4 with interval adjustments based on CST/VA up to 4-week increments or alternative 6-dose regimen then q8w; RVO—6 monthly doses.follow regimen-specific intervals and reassessments

    Source: Genentech, 2023.

    Ranibizumab products dosing: Lucentis/Cimerli/Byooviz: typical 0.5 mg monthly for nAMD and RVO; 0.3 mg monthly for DME/DR; mCNV dosing 0.5 mg monthly up to 3 months with retreatment PRN.monthly dosing (~28 days) per labeling

    Manufacturer prescribing information referenced.

    Susvimo implant dosing: Susvimo delivers ranibizumab 2 mg continuously with refills every 24 weeks for nAMD/DME and every 36 weeks for DR; supplemental 0.5 mg intravitreal injections may be given if clinically necessary; procedures require strict aseptic conditions.refill q24 or q36 weeks

    Source: Genentech, 2025c.

    Dosing / Administration (informational)

    Dosing and administration recommendations (agent-specific) — informational dosing guidance provided; coverage is contingent on meeting selection criteria elsewhere in the policy.

    Beovu (brolucizumab) DME/nAMD dosing: Beovu 6 mg: nAMD—monthly x3 then q8-12w maintenance; DME—every ~39-45 days for first five doses then q8-12w maintenance.as described

    Novartis, 2023.

    Vabysmo (faricimab) dosing regimens: Vabysmo 6 mg: nAMD—monthly x4 then individualized maintenance up to q16w; DME—monthly x>=4 with interval extension based on CST/VA or 6 monthly doses then q8w; RVO—monthly for 6 months.follow labeled regimens

    Genentech, 2023.

    Ranibizumab products dosing summary: Lucentis/Cimerli/Byooviz dosing: 0.5 mg monthly for nAMD/RVO/mCNV; 0.3 mg monthly for DME/DR; adjust per labeling and clinical response.monthly dosing per indication

    Manufacturer prescribing information.

    Susvimo implant administration: Susvimo implant: continuous 2 mg delivery with refill-exchange procedures every 24 weeks (nAMD/DME) or every 36 weeks (DR); supplemental 0.5 mg intravitreal injections if necessary; strict aseptic technique required.refill intervals as labeled

    Genentech, 2025c.

    Not Medically Necessary / Contraindications

    Not medically necessary / contraindication

    Contraindication: VEGF inhibitors for ocular indications are contraindicated and considered not medically necessary for persons with endophthalmitis or with ocular or periocular infections.N/A

    Per policy contraindication statement.

    Experimental/Investigational/Unproven

    Experimental, investigational, or unproven uses

    Aflibercept unproven indications: Aflibercept and listed biosimilars are considered experimental/investigational for indications including central serous chorioretinopathy, polypoidal choroidal vasculopathy, radiation retinopathy, retinitis pigmentosa, and selected non-ocular cancer indications.effectiveness not established

    See policy list for full items.

    Bevacizumab unproven ocular uses: Intravitreal or subconjunctival bevacizumab (and biosimilars) is considered experimental/investigational for amelanotic choroidal melanoma leakage, radiation maculopathy, hemorrhagic choroidal nevus, and subconjunctival use for bleb encapsulation/needling after trabeculectomy.effectiveness not established

    See policy list for full items.

    Ranibizumab and others unproven indications: Ranibizumab products, bevacizumab and biosimilars are considered experimental/investigational for amblyopia, central serous retinopathy, choroidal melanoma, Coat's disease, cystoid macular edema for non-approved settings, glaucoma surgery wound healing, hypertensive retinopathy, and vitreous hemorrhage not related to a medically necessary indication.effectiveness not established

    Concurrent use of >1 VEGF inhibitor in same eye is considered experimental/unproven.

    General coverage criteria for intravitreal VEGF inhibitors

    Covered when ALL of the following are met for the listed agents:

    Diagnosis: The treated eye has a diagnosis listed in the policy's covered ICD-10 codes appropriate to the drug (e.g., DME, RVO, neovascular AMD, ROP where specified).

    See coding module for exact code ranges.

    Billing and authorization: The provider bills an applicable HCPCS/J/Q code for the intravitreal agent and documents medical necessity and prior authorization as required by payer policy.

    PA may be required for listed HCPCS/J/Q codes per authorization module.

    Drug-label and safety: Use is consistent with FDA-approved indications and label contraindications/warnings are considered (e.g., avoid in active ocular/periocular infection, active intraocular inflammation).

    Monitor for known injection-related risks such as endophthalmitis and retinal detachment.

    Coverage aligned with FDA indications

    Covered when consistent with FDA-approved indications and dosing supported by pivotal trials:

    FDA-approved indication coverage: The agent is used for an FDA-approved ocular indication (e.g., neovascular AMD, macular edema following RVO, diabetic macular edema, diabetic retinopathy, ROP where labeled) and the documented dosing regimen aligns with trial-proven schedules (e.g., 2 mg q4w, 2 mg q8w after loading, or HD schedules per PULSAR).

    Supported by pivotal trials cited in the policy (VIEW, VISTA/VIVID, PULSAR, PHOTON, TENAYA/LUCERNE, YOSEMITE/RHINE, BALATON/COMINO).

    Evidence summaries (no explicit coverage rules in this segment)

    Evidence summaries and study findings relevant to potential coverage decisions

    Aflibercept for chronic CSC: Small prospective and pilot studies show short-term anatomical and some functional improvements (reduced CMT, some BCVA gains) but evidence is low quality and limited by small sample sizes; observation, PDT, or laser remain common approaches and RCT evidence is lacking.evidence: small studies; no robust RCT support

    Policy notes limited evidence for routine coverage.

    Aflibercept for POHS-associated CNV: Small prospective and randomized studies reported VA and OCT improvements with aflibercept; Toussaint randomized 39 eyes showed gains at 12 months.study sizes small to moderate

    Informational—no change to core coverage criteria.

    Aflibercept for RVO-related CME after prior anti-VEGF: A retrospective switch study (n=27) reported improved VA and decreased CFT after switching to aflibercept in eyes with persistent CME despite prior ranibizumab/bevacizumab; inclusion criteria included >=6 months prior treatment and CFT >=300 μm.prior anti-VEGF >=6 months and CFT >=300 μm in the studied cohort

    Supports prior-therapy documentation when requesting switches.

    Background evidence and compendial indications

    Evidence summaries and compendial uses

    Aflibercept in PCV: Prospective multi-center study of aflibercept monotherapy in PCV showed mean +13 ETDRS letters at 28 weeks and 62% polyp disappearance on ICGA after 5 injections in a small cohort.study endpoints

    Informational evidence supporting use in PCV.

    Aflibercept in ROP: Retrospective series reported short-term regression of ROP after aflibercept with some complete vascularization in a subset; long-term safety data limited.

    ROP indication limited to labeled products per policy.

    Bevacizumab compendial uses: Bevacizumab and biosimilars have compendial uses for DME, neovascular AMD, RVO macular edema, PDR, CNV, neovascular glaucoma, ROP, and PCV.compendial listing

    Informational background.

    Evidence-supported ocular indications (background)

    Indications supported by the cited evidence in this section (clinical trial and observational reports):

    Supported indications: Diabetic macular edema (DME); Macular edema due to retinal vein occlusion (BRVO/CRVO); Refractory pseudophakic cystoid macular edema; Diffuse diabetic macular edema; Iris neovascularization/neovascular glaucoma as adjunctive therapy; Chronic central serous chorioretinopathy (select cases).

    Evidence strength varies by indication (randomized trials to observational series).

    Use in neovascular AMD and rare CNV causes

    Covered when supported by evidence or biologic plausibility and diagnostic documentation as specified below

    Neovascular AMD (CATT-supported): Bevacizumab or biosimilars may be used for neovascular AMD when administered per trial-based regimens (CATT) demonstrating comparable visual outcomes to ranibizumab; prior authorization should consider trial-based indications and safety monitoring.

    Document treatment schedule and monitor for systemic AEs as noted in trials.

    Rare causes of CNV: Intravitreal bevacizumab may be indicated for visual loss due to active choroidal neovascularization (degenerative myopia, idiopathic, angioid streaks, trauma, choroiditis, retinal dystrophies) when active CNV is documented by fluorescein angiography or OCT.documentation of active CNV

    Use limited by rarity and absence of large RCTs; biologic plausibility supports therapy.

    Peri-operative and pre-operative adjunctive use in PDR and vitrectomy

    Use supported or investigational for selected surgical scenarios with timing considerations

    Peri-operative IVB to reduce early POVCH: Pre- or intra-operative intravitreal bevacizumab may reduce early post-operative vitreous hemorrhage in selected patients undergoing vitrectomy for PDR; evidence is mixed and case selection/ timing should be documented.

    Timing considerations: vascular regression occurs around day 5 and a pro-fibrotic switch increases contractile components by day ~10 post-injection.

    Pre-operative IVB timing before vitrectomy for PDR: Consider surgery timing approximately 5–10 days after IVB to balance vascular regression and fibrosis risk; evidence supportive but not definitive.

    Clinical judgment and documentation required.

    Other ophthalmic uses with limited evidence

    Uses reported in small trials or case series; often described as promising but requiring further study

    Chronic CSC: Small controlled studies and case series suggest possible benefit from intravitreal anti-VEGF (bevacizumab or aflibercept) in persistent chronic CSC, but randomized trial evidence is limited and routine use is not established.symptomatic persistent CSC (>=3 months) in select patients

    Policy classifies many CSC uses as investigational or of limited evidence.

    Pterygium (subconjunctival bevacizumab): Short-term reduction in vascularity and symptoms reported; no clear long-term benefit for recurrence prevention—consider investigational.

    Insufficient evidence for routine coverage.

    Neovascular glaucoma / rubeosis iridis: Case series report regression of iris neovascularization and short-term IOP reduction after intravitreal or intracameral bevacizumab; re-proliferation may occur—used as adjunctive therapy with close follow-up.

    Evidence limited and short-term.

    Clinical evidence-based indications (informational)

    Clinical recommendations and evidence summaries present in the text (informational):

    BRVO macular edema: Intravitreal anti-VEGF therapy is safe and effective for macular edema secondary to branch retinal vein occlusion; delayed treatment is associated with less improvement in VA.

    Level I evidence supports use.

    Radiation maculopathy/retinopathy: Intravitreal anti-VEGF administered periodically can slow vision loss and anatomic degradation in radiation maculopathy; evidence mainly from retrospective series and small studies.

    Consider anti-VEGF as first-line in many practices despite limited RCT data.

    Retinopathy of prematurity (Type 1): Intravitreal anti-VEGF agents are effective for regression of acute Type 1 ROP but require vigilant extended follow-up due to higher recurrence rates and uncertain long-term systemic effects in infants.

    Use judiciously and document risks and follow-up plan.

    Evidence summaries and approved indications

    Summaries of indications and trial findings (informational):

    ROP: Type I ROP: anti-VEGF agents (eg, bevacizumab, ranibizumab) are recommended for treatment rather than surveillance in appropriate cases; systemic VEGF suppression and long-term effects are uncertain—use judiciously.

    Informational—policy limits ROP coverage to labeled agents where specified.

    Brolucizumab (Beovu): Beovu approved for nAMD and DME; trials (HAWK/ HARRIER; KESTREL/KITE) demonstrate noninferiority to aflibercept with potential maintenance on q12w dosing in many patients; safety signals include intraocular inflammation and retinal vasculitis/occlusion.

    Informational.

    Faricimab (Vabysmo): Vabysmo approved for nAMD, DME, and macular edema following RVO; phase 3 trials (TENAYA/LUCERNE, YOSEMITE/RHINE, BALATON/COMINO) showed noninferiority to aflibercept and potential for extended dosing up to q16w.

    Informational.

    Coverage aligned with FDA-approved indications and trial evidence

    Coverage is anchored to FDA-approved indications supported by clinical trials and safety data.

    FDA-labeled indications: Use of ranibizumab (Lucentis/Cimerli/Byooviz) and faricimab (Vabysmo) for their FDA-approved ocular indications (e.g., nAMD, DME, RVO-related macular edema, diabetic retinopathy, mCNV) is supported by randomized controlled trial evidence described in referenced studies and is considered covered when selection criteria and dosing align with labeling.

    Trials cited include YOSEMITE/RHINE, TENAYA/LUCERNE, BALATON/COMINO, MARINA/ANCHOR, BRAVO/CRUISE, RISE/RIDE.

    Aetna considers the use of intravitreal VEGF inhibitors only for the specific ocular indications listed for each agent. All other indications not enumerated under each product’s Criteria for Initial Approval are considered not medically necessary, and experimental, investigational, or unproven. This applies to aflibercept (Eylea and listed biosimilars), bevacizumab (Avastin and listed biosimilars), brolucizumab (Beovu), and other named products unless an indication is explicitly listed as covered in the policy.

    For intravitreal faricimab (Vabysmo) and for intravitreal ranibizumab products (Lucentis, Cimerli, Byooviz) and Susvimo, Aetna explicitly states that uses beyond the listed FDA‑approved ocular indications are considered not medically necessary, and therefore experimental, investigational, or unproven. Continuation/reauthorization for these agents is permitted only when a positive clinical response is documented for an approved indication.

    Within the dosing and administration section the document notes that approvals may be subject to dosing limits aligned with FDA labeling, compendia, and evidence‑based guidelines, but this section does not present separate explicit exclusions beyond the agent‑specific "all other indications" statements; in other words, no additional standalone exclusion list is specified in that dosing/administration excerpt.

    Dosing guidance provided for individual products reflects labeled loading and maintenance schedules (for example, aflibercept dosing of 2 mg intravitreal monthly x3 then every 8 weeks for nAMD; brolucizumab 6 mg monthly x3 then every 8–12 weeks). The policy warns that deviation from recommended dosing frequency—particularly dosing more frequently than recommended—may not be supported by efficacy data for most patients and that approvals may be subject to dosing limits consistent with FDA labeling and medication quantity limits.

    The policy includes extensive lists of ICD‑10 diagnosis codes that are not considered appropriate indications for intravitreal VEGF therapy for the CPB‑listed indications. Examples of diagnoses listed as not covered include infectious and inflammatory ocular conditions (e.g., tuberculosis of the eye, zoster ocular disease, CMV retinitis), various conjunctivitides and surface inflammatory disorders, ocular neoplasms, and other non‑target retinal disorders. Providers should ensure the billed diagnosis code corresponds to a covered ocular indication for the selected drug.

    Multiple ICD‑10 code ranges and disease categories are presented as not covered for the CPB indications; these include, but are not limited to, infectious eye diseases (A18.x, B02.x, B25.9), conjunctivitis and surface inflammatory codes (H10.x, H01.x), malignant neoplasms of the globe (C69.x), and specified hereditary retinal dystrophies and other non‑covered retinal conditions. The policy notes these ICD‑10 entries as examples of diagnoses for which intravitreal VEGF therapy is not covered for the listed indications.

    Per product prescribing information and the policy summary, intravitreal VEGF inhibitors are contraindicated—and their use would not be supported—when there is an ocular or periocular infection, active intraocular inflammation, or known hypersensitivity to the product. The labels also highlight procedural risks (e.g., endophthalmitis, retinal detachment, acute IOP rise) and systemic warnings (potential arterial thromboembolic events) that factor into coverage and safety assessments.

    Although small studies and some case series report anatomic or functional improvement with aflibercept for myopic choroidal neovascularization, the policy states that the safety and effectiveness of aflibercept for this indication still require confirmation in large, rigorous clinical trials before being considered established therapy.

    For central serous chorioretinopathy (CSC), the evidence base is limited: trials are generally small, often at risk of bias, and many compared a variety of interventions (anti‑VEGF, PDT, laser, pharmacologic and other treatments). Because CSC commonly resolves spontaneously and randomized data are inconclusive, the document emphasizes that routine anti‑VEGF use for acute CSC is not clearly supported and higher‑quality RCTs are needed to define any definitive role.

    The policy cites UpToDate and other references in background sections and notes that some reviews (for example, on delayed complications of cranial irradiation and on retinitis pigmentosa treatment) do not list aflibercept as a recommended therapeutic option for those non‑standard indications, supporting the position that such uses are not established in standard references.

    Systematic reviews and evidence summaries cited in the background indicate that long‑term safety and efficacy data for some applications—particularly for bevacizumab and other anti‑VEGF agents in diabetic eye disease—remain limited, and higher‑quality studies are required. The policy highlights these evidence gaps and that insufficient long‑term data may limit routine authorization in certain diabetic retinopathy contexts.

    Small randomized trials of intra‑operative or single‑dose subconjunctival bevacizumab as an adjunct to pterygium surgery did not demonstrate a reduction in recurrence rate or meaningful improvements in early post‑operative signs; the policy therefore characterizes such subconjunctival uses as lacking demonstrated benefit in these settings.

    A retrospective series cited in the policy found that prophylactic intravitreal bevacizumab did not reduce the incidence of radiation retinopathy after stereotactic radiotherapy for choroidal melanoma in that cohort. The document therefore notes that prophylactic intravitreal bevacizumab for prevention of radiation retinopathy is not supported by that study and requires further research.

    The prescribing information summaries included in the policy reiterate key contraindications common across agents: ocular or periocular infection, active intraocular inflammation, and hypersensitivity. These label contraindications are noted as potential reasons for denying or withholding intravitreal VEGF therapy.

    The policy notes that pegaptanib (Macugen) has been discontinued and is no longer available in the U.S. It also highlights that anti‑VEGF therapy for uncommon indications such as hypertensive retinopathy is described only in case reports or small series and is not supported by standard references like UpToDate, indicating limited or non‑routine use.

    Consistent with the agent‑specific statements, the policy reiterates that use of the named intravitreal VEGF agents for any indication not specifically listed under that product is considered not medically necessary, experimental, investigational, or unproven. This blanket NMN stance applies across aflibercept, bevacizumab, brolucizumab and other listed agents when the indication is not in the policy’s covered indications.

    Specifically for faricimab (Vabysmo), the policy states that intravitreal use outside of the listed conditions (DME, neovascular AMD, and macular edema following RVO) is considered not medically necessary, experimental, investigational, or unproven; continuation is allowed only with documented positive response for an approved indication.

    For ranibizumab products (Lucentis, Cimerli, Byooviz) and for ranibizumab injection via the Susvimo implant, the policy declares that all other uses beyond the listed covered indications are not medically necessary, experimental, investigational, or unproven. Susvimo also requires prior documented response to at least two intravitreal VEGF injections within the prior 6 months as part of its coverage criteria.

    Some background and dosing excerpts do not include explicit "not medically necessary" statements for every agent‑indication combination; in those sections the document focuses on dosing limits, labeling, and evidence summaries rather than re‑stating NMN conditions. Nevertheless, the policy’s coverage tables and agent‑specific sections do articulate NMN determinations where applicable.

    Billing and Diagnosis Codes

    Products referenced (codes not shown)mixed
    Not specified in this partDocument lists product names (aflibercept/Eylea and biosimilars, brolucizumab/Beovu, faricimab/Vabysmo, ranibizumab/Lucentis/Susvimo and biosimilars, bevacizumab/Avastin and biosimilars) but specific CPT/HCPCS/ICD-10 codes are provided elsewhere in the Codes section.
    No explicit CPT/HCPCS/ICD codes in this sectionmixed
    No codes listed
    Covered CPT / Related and HCPCS codes (brolucizumab example)mixedCovered
    67028Intravitreal injection of a pharmacologic agent (separate procedure).
    92081Visual field examination, limited.
    92082Visual field examination, intermediate.
    92083Visual field examination, extended.
    99172Visual function screening, automated or semi-automated.
    99173Screening test of visual acuity, quantitative, bilateral.
    J0179Injection, brolucizumab-dbll, 1 mg.
    Covered HCPCS codes for ranibizumab / bevacizumab and biosimilarsHCPCSCovered
    J2779Injection, ranibizumab, via intravitreal implant (Susvimo), 0.1 mg.
    C9257Injection, bevacizumab, 0.25mg [Avastin] [intraocular dose].
    J9035Injection, bevacizumab, 10 mg [Avastin] [chemotherapy dose].
    Q5107Injection, bevacizumab-awwb (Mvasi), 10 mg.
    Q5118Injection, bevacizumab-bvzr (Zirabev), 10 mg.
    Q5124Injection, ranibizumab-nuna (Byooviz), 0.1 mg.
    Q5126Injection, bevacizumab-maly (Alymsys), 10 mg.
    Q5128Injection, ranibizumab-eqrn (Cimerli), 0.1 mg.
    Q5129Injection, bevacizumab-adcd (Vegzelma), 10 mg.
    Q5160Injection, bevacizumab-nwgd (Jobevne), 10 mg.
    ICD-10 codes covered if selection criteria are metICD-10Covered
    H35.3210 - H35.3293Exudative age-related macular degeneration.
    E08.311 - E08.37X9Diabetes mellitus with retinopathy with macular edema (various subcodes listed).
    H34.8110 - H34.8192Central retinal vein occlusion.
    H34.8310 - H34.8392Branch retinal vein occlusion [with macular edema].
    H44.2A1 - H44.2A9Degenerative myopia with choroidal neovascularization.
    CPT codes not covered / related (examples not covered for CPB indications)CPTNot Covered
    66030Injection, anterior chamber of eye (separate procedure); medication.
    68200Subconjunctival injection.
    67027Implantation of intravitreal drug delivery system (includes concomitant removal of vitreous).
    Covered HCPCS / ICD-10 codes referenced (broader list)mixedCovered
    H35.3210 - H35.3293Exudative age-related macular degeneration.
    H35.33Angioid streaks of macula.
    H35.50 - H35.54Hereditary retinal dystrophies.
    H40.89Other specified glaucoma [associated with vascular disorders].
    H44.2A1 - H44.2A9Degenerative myopia with choroidal neovascularization.
    M31.8Other specified necrotizing vasculopathies [polypoidal choroidal vasculopathy].
    Q82.8Other specified congenital malformations of skin [pseudoxanthoma elasticum].
    J0177Injection, aflibercept HD, 1 mg.
    J0178Injection, aflibercept, 1 mg.
    Q5147Injection, aflibercept-ayyh (Pavblu), biosimilar, 1 mg.
    1–10 of 20
    1/2
    ICD-10 codes listed as not covered (examples)ICD-10Not Covered
    A18.50 - A18.59Tuberculosis of eye (listed among ICD-10 codes not covered for indications in CPB).
    A51.43Secondary syphilitic oculopathy [chorioretinitis] (not covered).
    B02.30 - B02.39Zoster ocular disease (not covered).
    B25.9Cytomegalovirus disease (retinitis) (not covered).
    C69.20 - C69.32Malignant neoplasm of retina and choroid (not covered).
    H00.011 - H00.029Hordeolum externum (not covered).
    H01.001 - H01.009Blepharitis (not covered).
    Covered HCPCS codes (aflibercept)HCPCSCovered
    J0178Injection, aflibercept, 1 mg.
    Clinical trial identifiers and study namesmixed
    NCT02307682HAWK clinical trial identifier.
    NCT02434328HARRIER clinical trial identifier.
    KESTRELPhase 3 trial for brolucizumab in DME.
    KITEPhase 3 trial for brolucizumab in DME.
    TENAYAPhase 3 trial for faricimab in nAMD.
    LUCERNEPhase 3 trial for faricimab in nAMD.
    YOSEMITEPhase 3 trial for faricimab in DME.
    RHINEPhase 3 trial for faricimab in DME.
    BALATONPhase 3 trial for faricimab in branch RVO-associated macular edema.
    COMINOPhase 3 trial for faricimab in central/hemiretinal RVO-associated macular edema.
    No explicit CPT/HCPCS/ICD-10/NDC codes in this segmentmixed
    No codes listed
    Retinopathy of prematurity minimum interval — treatment spacing detail
    Minimum interval (same eye)Treatment interval between doses injected into the same eye should be at least 10 days.
    ROP recommended dose (Eylea)0.4 mg (0.01 mL) intravitreal per injection; may be given bilaterally same day; injections may be repeated.
    Context/sourceRegeneron prescribing information as cited in policy (Regeneron, 2023b).
    Dosing intervals / regimen checkpoints — dosing schedule checkpoints and examples
    Beovu (brolucizumab) initial/maintenance checkpoint6 mg monthly for first 3 doses (nAMD) then every 8–12 weeks; for DME 6 mg every ~39–45 days for first five doses then every 8–12 weeks.
    Vabysmo (faricimab) checkpoint example6 mg monthly ×4 then OCT/VA assessments at weeks 8 and 12 to select individualized maintenance (examples: weeks 28 & 44; 24,36,48; or 20,28,36,44); some patients may require monthly dosing after initial doses.
    Ranibizumab (Lucentis) exampleLucentis 0.5 mg: monthly (~28 days) for nAMD and RVO; 0.3 mg monthly for DME/DR; initial 3 monthly doses often used before extending intervals.
    Susvimo implant checkpointSusvimo delivers continuous ranibizumab with refill-exchange intervals (refill q24 weeks for nAMD/DME; q36 weeks for DR); supplemental 0.5 mg intravitreal injections allowed if clinically necessary.
    Age distribution in trials — demographic note
    Age ≥65 representationApproximately 76% of patients randomized to Eylea were 65 years of age or older (2049/2701).
    Age ≥75 representationApproximately 46% of patients randomized to Eylea were 75 years of age or older (1250/2701).
    Trial contextReported in Eylea clinical studies (VIEW and related trials) as cited in the policy.
    Central foveal thickness (CFT) threshold used in switch study — numeric threshold
    CFT threshold used in switch study>= 300 μm (central foveal thickness at time of switch to aflibercept)
    Study contextInclusion criterion for Spooner et al. retrospective switch study of RVO-related CME (eyes had CFT ≥300 μm at time of switch).
    Outcome measures referencedCFT measured by OCT used as anatomic outcome in study reporting decrease after switch.
    BCVA change in aflibercept PCV study — numeric outcome
    Mean BCVA change (PCV study)+13 ETDRS letters (mean change from baseline at 28 weeks).
    Study contextProspective multi-center aflibercept monotherapy study in PCV (34 eyes) after 5 injections over 28 weeks.
    Polyp regression note62% polyp disappearance on ICGA after 5 injections reported alongside BCVA gain.

    Precertification, Prior Authorization, and Documentation Requirements

    Prior Authorization

    Precertification required

    Precertification is required for listed intravitreal VEGF inhibitors for all Aetna participating providers and members in applicable plan designs; call (866) 752-7021 or fax (888) 267-3277 and submit Statement of Medical Necessity (SMN) forms via Specialty Pharmacy Precertification.

    • Precertification applies to listed products including aflibercept (Eylea, biosimilars), brolucizumab (Beovu), faricimab (Vabysmo), ranibizumab (Lucentis, Susvimo, biosimilars).
    Step Therapy

    Susvimo prior-response requirement

    For Susvimo (ranibizumab intravitreal injection/implant), the member must have previously responded to at least two intravitreal injections of a VEGF inhibitor (e.g., Avastin, Eylea) within the past 6 months before Susvimo is considered medically necessary.

    Prior Authorization

    Dosing limits and Susvimo implant

    Approvals may be subject to dosing limits consistent with FDA labeling, accepted compendia, and Aetna specialty medication quantity limits; the Susvimo implant is considered medically necessary only when criteria for intravitreal ranibizumab injection are met.

    • Dosing limits referenced to Medical Specialty Medication Quantity Limits.
    • Susvimo implant use tied to meeting intravitreal ranibizumab (Susvimo) criteria.
    Note

    Use manufacturer dosing schedules for authorization

    When requesting authorization, reference the manufacturer's FDA-approved dosing schedules for the specific product (for example, aflibercept 2 mg schedules, brolucizumab 6 mg schedules) as the rationale for the requested regimen.

    • Aflibercept: typical 2 mg loading then q8w maintenance (product-specific variations in chunks 55–66).
    • Brolucizumab: 6 mg loading then q8–12w maintenance (chunks 71–72).
    Billing Rule

    Coverage tied to listed CPT/HCPCS/ICD-10 codes

    Coverage and billing should be linked to the CPT/HCPCS/ICD-10 codes listed in the policy; these procedure and drug codes are covered when the policy selection criteria are met (examples include CPT 67028 and listed J/Q HCPCS codes and the covered ICD-10 diagnosis ranges).

    • Example procedure code: 67028 (intravitreal injection).
    • Example HCPCS/J/Q codes listed for agents (see policy code tables).
    • Covered ICD-10 ranges tied to indications (e.g., H35.3210–H35.3293 for exudative AMD; E08–E13 series for diabetic retinopathy/DME).
    Prior Authorization

    PA required when billing listed injectable codes

    Prior authorization is required when billing the listed HCPCS/J/Q codes for intravitreal VEGF inhibitors and biosimilars; coverage is contingent on meeting selection criteria and appropriate ICD-10 diagnosis linkage.

    • Examples of injectable codes requiring PA include J0177, J0178, J2777 and multiple Q-codes and J-codes listed in the code tables.
    • Ensure submitted diagnosis codes correspond to the covered ICD-10 ranges in the policy.
    Prior Authorization

    Document indication and dosing for PA

    Prior authorization requests must document the specific ocular indication and the dosing regimen intended (e.g., 2 mg q4w or q8w for aflibercept, or HD dosing per PULSAR) to support approval.

    • Indicate indication (DME, nAMD, RVO, etc.) and specific dosing schedule per product label.
    • Include whether loading then maintenance schedule is planned (product-specific).
    Note

    PA background (no new PA codes specified)

    (Background note) This background section provides clinical context and does not itself specify additional prior authorization codes or requirements beyond the policy's PA statements and code tables.

    Documentation Required

    Document prior therapy and OCT/VA when switching for RVO‑CME

    When switching therapy for persistent CME after prior ranibizumab/bevacizumab, prior authorization should document prior anti‑VEGF treatment history and objective measures such as central foveal thickness (CFT ≥300 μm) and visual acuity at time of switch.

    • Document duration and number/dates of prior injections and baseline CFT (≥300 μm used in the reported switch study).
    • Provide rationale for switch to aflibercept with supporting OCT/VA data.
    Note

    Prior authorization (no details in excerpt)

    (Not present) This block placeholder corresponds to a segment not included in the excerpt and therefore does not add specific PA actions.

    Documentation Required

    Support PA with diagnosis, BCVA, OCT, prior injections

    Prior authorization requests should be supported by documented diagnosis, baseline and follow‑up best-corrected visual acuity (BCVA) and OCT measurements, and the number and dates of prior intravitreal injections to demonstrate medical necessity.

    • Include BCVA/ETDRS scores and OCT-measured retinal thickness (CFT/CST) at baseline and follow-up.
    • List prior treatment history (agent, dose, dates, number of injections).
    Note

    CATT evidence may support bevacizumab PA decisions

    Clinical evidence from randomized trials (for example, CATT) supports bevacizumab use for neovascular AMD with visual outcomes comparable to ranibizumab; prior authorization should consider such trial-based indications and weigh safety signals noted in trials.

    • CATT showed equivalence in VA at 1 year between bevacizumab and ranibizumab; monitor for higher serious systemic adverse events with bevacizumab reported in CATT.
    Note

    PA background (clinical evidence only)

    (Background only) This section provides clinical background and evidence summaries and does not specify additional prior authorization requirements in this excerpt.

    Prior Authorization

    Specify drug and regimen in PA request

    Include the specific drug and regimen in the prior authorization request (for example, brolucizumab 6 mg with planned q8/q12‑week maintenance after loading; faricimab 6 mg up to q16w or PTI schedules) and provide clinical justification.

    • State intended maintenance interval (e.g., q12w, q16w) and disease-activity assessment schedule used to justify extended intervals.
    • If requesting HD or non-standard dosing reference the supporting trial (e.g., PULSAR).
    Prior Authorization

    PA for labeled indications: document diagnosis, prior therapy, findings

    For FDA‑approved labeled indications, prior authorization typically requires documentation of diagnosis, prior treatments as applicable, and clinical findings demonstrating ongoing need aligned with labeled use.

    • Confirm the request is for an FDA‑approved ocular indication (nAMD, DME, RVO‑associated macular edema, DR, ROP for specified agents).
    • Provide dosing regimen consistent with product labeling and trial‑based schedules.
    Step Therapy

    Brand selection / step therapy may apply

    Aetna commercial plans may require trial of a lower‑cost preferred medication within the same therapeutic class before approving a higher‑cost drug; refer to the Aetna Commercial Clinical Program Summary for preferred drug lists.

    • Check plan-level preferred drug requirements prior to requesting higher-cost agents.
    • Document trial of preferred agent and response when applicable.
    Prior Authorization

    Susvimo prior‑response summary for PA

    Summary: Susvimo implant is only covered after demonstration of prior response to at least two intravitreal injections of a VEGF inhibitor within the past 6 months; document prior response and that implant will be used as required.

    • Ensure Susvimo PA includes dates and agents of the two prior responsive intravitreal injections.
    • Confirm implant will be used in conjunction with intravitreal ranibizumab injection per labeling.
    Prior Authorization

    Include loading to maintenance dosing in authorization plan

    When authorizing initial courses, note loading followed by maintenance intervals per product labeling (for example, monthly loading doses then transition to q8w or individualized intervals) and document planned schedule in the request.

    • Aflibercept typical loading: monthly x3 (or x5 for DME) then every 8 weeks maintenance per product.
    • Beovu and Vabysmo have specified loading/maintenance schedules—include these in PA rationale.
    Denial Risk

    Concurrent VEGF inhibitors in same eye not accepted

    Concurrent use of more than one VEGF inhibitor in the same eye is considered experimental, investigational, or unproven and is not an accepted therapy sequence; do not request simultaneous agents for the same eye.

    • If considering multiple agents, document rationale and acknowledge policy states combinational use in same eye is experimental/unproven.
    Note

    Use comparative trial context in PA rationale

    Clinical trials comparing aflibercept with ranibizumab or laser (and other comparative studies) may be used to justify choices in PA requests and support sequencing decisions when prior therapies were tried.

    • Reference relevant trial data (e.g., VIEW, VISTA/VIVID) when justifying use of aflibercept over alternatives.
    Documentation Required

    Document prior therapy trials when requesting switches

    Consider documenting prior trials of alternative anti‑VEGF agents or PDT when requesting a switch to another agent for refractory disease; prior therapeutic trials reported in literature may inform approval decisions.

    • For refractory PCV or CNV, include prior therapy history and imaging (ICGA/OCT) demonstrating lesion characteristics and prior response.
    Documentation Required

    Provide prior treatment history to justify therapeutic sequencing

    Therapeutic sequencing (e.g., switching from ranibizumab to aflibercept after failure or combining with PDT) is described in the literature; when used to justify a non-standard sequence, provide prior treatment history and objective measures.

    Step Therapy

    Step therapy may consider laser alternatives

    When step‑therapy considerations involve laser photocoagulation as an alternative, document why anti‑VEGF is preferred and reference comparative trials versus macular laser where applicable.

    • If electing anti‑VEGF instead of laser, include OCT/VA evidence and rationale referencing trial results showing benefit over delayed or no anti‑VEGF.
    Note

    CATT comparative data may inform step therapy

    Comparative effectiveness data such as CATT showing similar efficacy between bevacizumab and ranibizumab may be cited in step‑therapy decisions between agents.

    Note

    Step therapy: no explicit sequencing mandated in excerpt

    (Informational) CATT and other comparative trials are discussed in the background but no explicit step therapy sequencing is mandated in the policy excerpt.

    Documentation Required

    How to precertify (phone/fax and SMN forms)

    Precertification can be obtained by phone at 866-752-7021 or by fax at 888-267-3277; Statement of Medical Necessity (SMN) precertification forms are available through Specialty Pharmacy Precertification.

    Documentation Required

    Document positive clinical response (BCVA/OCT) for continuation

    Document clinical evidence of positive response for continuation or reauthorization requests, including BCVA (ETDRS or Snellen) and OCT measures showing decreased retinal thickness or stable/improved vision.

    • Include comparative BCVA measures (baseline and follow-up) and OCT central subfield thickness or CFT trends to support continuation.
    • State whether response represents improvement or maintenance of vision per policy continuation criteria.
    Documentation Required

    Document Susvimo implant use and dosing per label

    For Susvimo implant requests, document that use is accompanied by ranibizumab intravitreal injection and that dosing aligns with FDA labeling and referenced prescribing information; note refill intervals and any supplemental injections planned.

    • State Susvimo refill plan (refill-exchange every 24 weeks for nAMD/DME or every 36 weeks for DR) and any anticipated supplemental 0.5 mg intravitreal injections.
    • Confirm strict aseptic conditions for implantation and refill procedures.
    Documentation Required

    Cite manufacturer/trial sources for nonstandard dosing

    When using nonstandard regimens or supporting alternative dosing, cite manufacturer prescribing information or the referenced pivotal trials as justification in the prior authorization submission.

    • Provide manufacturer source and year (e.g., Celltrion USA 2025 for Eydenzelt; Novartis 2023 for Beovu) when requesting deviations from standard schedules.
    Documentation Required

    Susvimo procedures require strict aseptic technique

    Initial implantation, refill‑exchange, and implant removal procedures for Susvimo require strict aseptic technique; document that procedures will be performed under such conditions.

    Billing Rule

    Link ICD-10 diagnosis codes to documented clinical findings

    Required diagnostic documentation must link the billed ICD-10 diagnosis to the documented clinical findings (for example, diabetes with retinopathy codes for DME or H34.8110–H34.8192 for CRVO with macular edema).

    • Ensure submitted ICD-10 codes correspond to the covered ranges in the policy and include supporting clinical evidence (OCT/VA).
    Documentation Required

    Include supporting trial identifiers and regimens in PA

    When requesting authorization, list the pivotal trials and their dosing regimens that support the indication (examples: BUTTERFLEYE, FIREFLEYE, PULSAR for aflibercept; TENAYA/LUCERNE for faricimab) as applicable to the clinical rationale.

    • Reference trial endpoints (BCVA changes at specified timepoints) and how the requested regimen aligns with trial protocols.
    Documentation Required

    Provide prior treatment history and objective measures for switches

    For switches or continuation, include prior treatment history and objective outcome measures (BCVA and OCT) as recommended clinical documentation to justify ongoing or altered therapy.

    • For RVO‑CME switch cases include prior anti‑VEGF duration/number of injections and baseline CFT (≥300 μm where study criteria applied).
    • For PCV or POHS CNV include ICGA/OCT lesion characterization and prior response to therapy.
    Documentation Required

    Required clinical outcome documentation for PA

    Document required clinical outcomes to support authorization such as BCVA/ETDRS scores, OCT-measured retinal thickness (CFT/CST), and treatment history (number and dates of prior intravitreal injections).

    • Provide baseline and follow-up BCVA and OCT/CFT measurements; list prior injection dates and agents.
    Documentation Required

    Document FDA indication, regimen, and disease‑activity evidence

    Required clinical documentation for authorization should include the FDA‑approved indication, the dosing regimen used (including loading and maintenance intervals), and evidence of disease activity guiding the chosen interval.

    • Specify whether extended intervals (e.g., faricimab up to q16w) are based on protocol-defined disease‑activity assessments and provide those assessment results.
    Documentation Required

    Use trial efficacy endpoints to support authorization

    Use trial efficacy endpoints (e.g., change in BCVA at 6 or 24 months) and diagnosis‑specific trial results when providing efficacy documentation to support authorization for long‑term or high‑cost regimens.

    Denial Risk

    Failure to precertify may risk noncoverage

    Failure to obtain precertification for listed VEGF inhibitors may result in noncoverage or denial of payment.

    Denial Risk

    Off‑label indications may be denied

    Use of agents for indications other than those listed (for example, faricimab beyond DME, nAMD, and RVO) is considered not medically necessary and may be denied if requested for unlisted indications.

    Denial Risk

    Non‑listed Susvimo/ranibizumab uses considered NMN

    Use of ranibizumab products or the Susvimo implant for indications not listed in the policy is considered not medically necessary/experimental and may be denied.

    Denial Risk

    Dosing limits and frequency deviations may affect approval

    Approvals may be subject to dosing limits in accordance with FDA labeling, accepted compendia, and evidence‑based practice guidelines; requests for more frequent dosing than recommended may not be supported.

    • Deviations to more frequent dosing should include efficacy justification and supporting trial or manufacturer evidence.
    Denial Risk

    More‑frequent‑than‑label dosing may not be supported

    Dosing more frequently than recommended (for example, more frequent than manufacturer‑specified intervals) may not be supported by efficacy data and could risk non‑approval.

    Denial Risk

    Ocular infection/endophthalmitis is denial trigger

    VEGF inhibitors are contraindicated and would be denied for persons with endophthalmitis or ocular/periocular infection; document absence of these contraindications.

    • Contraindications per label also include active intraocular inflammation and hypersensitivity—these would likely lead to denial.
    Billing Rule

    Diagnosis‑code linkage required for coverage

    Use of specific ICD‑10 codes is required for coverage of certain drugs; absence of a covered diagnosis code (for example, diabetes with retinopathy codes for DME or H34.8110–H34.8192 for CRVO) may trigger denial.

    • Ensure billed ICD‑10 codes match the covered ranges listed in the policy code tables to avoid denial.
    Denial Risk

    Label contraindications may lead to denial

    Contraindications per product labels include ocular or periocular infection, active intraocular inflammation, and hypersensitivity; use in these conditions would likely be denied.

    Note

    Procedural/coverage denial triggers not specified here

    (Placeholder) Specific procedural or other coverage denial triggers are not detailed in the excerpted background and trial sections.

    Denial Risk

    Limited CSC evidence may affect authorization

    Because evidence for many interventions in central serous chorioretinopathy (CSC) is low quality and inconsistent, lack of strong RCT evidence may lead to denial or requests for additional justification for aflibercept use in CSC.

    Note

    Not applicable (no excerpt content)

    (Placeholder) No actionable requirement present in the excerpt for this block.

    Denial Risk

    Safety evidence gaps may affect authorization

    Potential systemic safety evidence gaps (for example, arterial thromboembolic events) in diabetic patients and other safety concerns may affect authorization decisions if safety data are inadequate for a given patient.

    • Document comorbidities and risk factors when requesting therapy for high‑risk patients.
    Documentation Required

    Require documentation of active CNV for rare indications

    Use for rare causes of choroidal neovascularization should be limited to patients with visual loss due to active CNV documented by fluorescein angiography or OCT; absence of such documentation may risk denial.

    • Provide FA or OCT evidence of active CNV when requesting bevacizumab for rare CNV indications.
    Note

    Background — no explicit PA triggers here

    (Placeholder) No specific PA/denial triggers are stated in these background excerpts for this block.

    Denial Risk

    ROP safety/ documentation may affect authorization

    Use of anti‑VEGF agents in premature infants requires judicious consideration because systemic VEGF suppression and long‑term effects are uncertain; insufficient documentation of indication/severity for type I ROP could risk denial.

    • When treating ROP, document severity (Type I, zone, plus disease), rationale for anti‑VEGF vs laser, and plans for extended follow‑up.
    Denial Risk

    Serious adverse events/contraindications affect authorization

    Contraindications, serious adverse events (ocular/periocular infection, hypersensitivity, endophthalmitis) and documented safety concerns are important safety‑related authorization risks and may lead to denial.

    Background and Clinical Evidence

    Intravitreal VEGF inhibitors are a class of agents administered for retinal vascular and neovascular disorders (e.g., DME, diabetic retinopathy, macular edema from RVO, neovascular AMD, and, for select agents, ROP). They work by inhibiting VEGF‑mediated vascular permeability and neovascularization and are approved for multiple ocular indications when used according to labeled dosing regimens and applicable trial‑supported schedules.

    Definitions and Key Terms

    Continuation of therapy — reauthorization definition and response criteria
    Reauthorization definitionReauthorization (continuation of therapy) is considered medically necessary when the member previously approved for an initial indication has demonstrated a positive clinical response (e.g., improvement or maintenance in BCVA or visual field, or reduced rate of vision decline).
    Required documentation for reauthorizationDocument diagnosis, baseline and follow-up BCVA and OCT measurements, and number/dates of prior injections to support continued therapy.
    Prescriber requirementTreatment must be prescribed by or in consultation with an ophthalmologist per policy statements.
    Positive clinical response — definition and examples (BCVA, visual field, OCT)
    Core definitionPositive clinical response is improvement or maintenance in best-corrected visual acuity (BCVA) or visual field, or a reduction in the rate of vision decline or risk of more severe vision loss.
    Examples (functional)Improvement or stability in BCVA measured by ETDRS letters (e.g., gains of ≥5–15 letters as used in trials).
    Examples (anatomic)Reduction in central macular/central foveal thickness (CMT/CFT) on OCT and decreased intraretinal/subretinal fluid as objective anatomic response measures.
    Susvimo ocular implant — definition and implant-context notes
    Susvimo implant definitionThe Susvimo ocular implant is an intraocular device that continuously delivers ranibizumab and is used in conjunction with intravitreal ranibizumab injections for approved indications when policy criteria are met.
    Implant context noteUse of Susvimo requires prior demonstrated response to at least two intravitreal VEGF injections within the past 6 months for Susvimo candidacy per policy criteria.
    Procedure conditionInitial implantation, refill-exchange, and implant removal require strict aseptic technique; refills occur at recommended intervals (see Susvimo dosing).
    Ranibizumab (Susvimo) ocular implant — implant delivery summary
    Delivery summarySusvimo is an ocular implant that continuously delivers ranibizumab (2 mg) and must be used with intravitreal ranibizumab injection (Susvimo) per policy; implant therapy is medically necessary only when Susvimo criteria are met.
    Refill & supplemental dosingRefill-exchange intervals: every 24 weeks for nAMD/DME and every 36 weeks for diabetic retinopathy; supplemental 0.5 mg intravitreal ranibizumab injections may be administered if clinically necessary.
    Prior-response requirementMember must have previously responded to at least two intravitreal injections of a VEGF inhibitor within the past 6 months before Susvimo is considered.
    Loading dose — definition and purpose
    Loading dose (definition)Initial monthly intravitreal injections administered for the first specified doses (commonly 3 monthly doses) to achieve initial disease control before transitioning to maintenance intervals.
    PurposeProvides early and consistent drug exposure to reduce retinal fluid and improve BCVA prior to spacing injections per maintenance regimens.
    ExamplesAflibercept/Lucentis protocols often use 3 monthly loading doses for nAMD; some DME regimens use 4–5 initial monthly doses before extending intervals.
    Maintenance dosing — definition and typical intervals
    Maintenance dosing (definition)Ongoing intravitreal injection intervals after the loading phase, tailored to product labeling and disease activity (commonly every 8 weeks for aflibercept biosimilars; every 8–12 weeks for brolucizumab; individualized intervals for faricimab).
    Typical intervalsExamples: aflibercept 2 mg once every 8 weeks after loading; brolucizumab 6 mg every 8–12 weeks after loading; faricimab individualized up to every 16 weeks in some trials.
    Adjustment principleMaintenance intervals may be shortened (return to monthly) if response inadequate; regular OCT/VA assessments guide interval changes.
    Susvimo implant — refill interval and implant note
    Refill interval (Susvimo)Susvimo refill-exchange recommended every 24 weeks for nAMD/DME and every 36 weeks for diabetic retinopathy.
    Implant noteThe implant continuously delivers ranibizumab and may require supplemental intravitreal injections if clinically necessary between refills.
    Procedure requirementRefill-exchange and implant procedures require strict aseptic conditions as noted in manufacturer guidance.
    Neovascular (wet) AMD — definition
    DefinitionNeovascular (wet) AMD is the form of age-related macular degeneration characterized by abnormal choroidal neovascularization driven by VEGF, causing rapid central vision loss from leakage, hemorrhage, and scarring.
    Clinical significanceNeovascular AMD is a leading cause of painless central vision loss in older adults and is a primary indication for intravitreal anti-VEGF therapy.
    Age contextAMD primarily affects older adults; clinical trials for aflibercept included high proportions of patients ≥65 and ≥75 years of age.
    Central Retinal Vein Occlusion (CRVO) — definition
    DefinitionCentral retinal vein occlusion (CRVO) is retinal venous occlusion causing retinal ischemia, increased VEGF production, macular edema, and possible neovascularization; it has ischemic and non-ischemic subtypes.
    Clinical consequenceCRVO can lead to macular edema and growth of fragile new blood vessels; treatment options include anti-VEGF injections for macular edema.
    Related conditionBranch retinal vein occlusion (BRVO) affects a smaller vessel branch and can also cause macular edema treatable with anti-VEGF therapy.
    Diabetic Macular Edema (DME) — definition
    DefinitionDiabetic macular edema (DME) is retinal vascular leakage and macular thickening from diabetic microvascular disease leading to central vision impairment; VEGF-mediated permeability is a key mechanism.
    Treatment roleAnti-VEGF agents are a principal therapy for DME, with trial-proven BCVA gains and OCT-guided retreatment strategies.
    Trial supportVISTA/VIVID and other trials demonstrated mean BCVA improvements with aflibercept in DME versus control arms.
    Polypoidal Choroidal Vasculopathy (PCV) — definition
    PCV definitionPolypoidal choroidal vasculopathy (PCV) is an exudative chorioretinopathy characterized by polyp-like choroidal vascular lesions and sero-sanguineous pigment epithelial detachments; it may be under-diagnosed and can be managed with anti-VEGF and PDT.
    Subtype notePCV is considered a subtype of neovascular AMD with branching vascular networks and aneurysmal polypoidal lesions; prevalence is higher in Asian populations.
    Therapeutic contextAnti-VEGF monotherapy (e.g., aflibercept) and combination with PDT have been used; some trials show polyp regression and BCVA gains.
    BCVA — definition as trial endpoint
    BCVA definitionBest-corrected visual acuity (BCVA) is measured by the Early Treatment Diabetic Retinopathy Study (ETDRS) chart and is a primary efficacy endpoint in many retinal trials.
    Measurement unitBCVA change is often reported as ETDRS letter score change (e.g., +13 letters) or proportion gaining ≥15 letters.
    Use in authorizationDocumented BCVA at baseline and follow-up is required to support continuation/reauthorization per policy documentation guidance.
    PRN — definition (pro re nata)
    PRN definitionPRN (pro re nata) denotes as-needed dosing after an initial fixed dosing phase, with retreatment based on disease activity (OCT/VA) to reduce injection frequency.
    Trial usagePRN approaches were used in some aflibercept trials after fixed dosing periods to maintain BCVA gains with monthly evaluations.
    Clinical implicationPRN requires regular monitoring (monthly) to determine retreatment necessity based on OCT and visual acuity findings.
    BCVA — trial measurement reference
    BCVA measurement referenceBCVA in trials is measured by ETDRS letter score and used as primary efficacy endpoint (e.g., change from baseline at specified weeks).
    Example endpointsPrimary endpoint examples: mean change in BCVA at week 48 (PULSAR) or averaged weeks 40/44/48 (TENAYA/LUCERNE).
    Documentation useBCVA values should be included in prior authorization and continuation documentation to demonstrate response.
    ETDRS-DRSS — definition
    ETDRS-DRSS definitionETDRS-DRSS (Early Treatment Diabetic Retinopathy Study Diabetic Retinopathy Severity Scale) is used to assess diabetic retinopathy changes and was an outcome in PHOTON and PULSAR-related assessments.
    Use in trialsETDRS-DRSS scores were assessed at baseline and approximately every 3 months in relevant trials to evaluate DR severity change.
    Regulatory relevanceETDRS-DRSS endpoints informed efficacy assessments for aflibercept HD in diabetic retinopathy trials.
    Central serous chorioretinopathy (CSC) — definition
    CSC definitionCentral serous chorioretinopathy (CSC) is characterized by serous detachment of the neurosensory retina related to choroidal and RPE dysfunction; often self-limited but can be chronic with risk of photoreceptor/RPE damage.
    Clinical courseMany acute CSC cases resolve spontaneously; treatments (PDT, laser, anti-VEGF) have limited high-quality RCT evidence for superiority.
    Implication for coverageBecause evidence is limited, routine anti-VEGF use for acute CSC is not strongly supported without compelling justification.
    Polypoidal choroidal vasculopathy (PCV) — subtype definition
    PCV subtype definitionPolypoidal choroidal vasculopathy (PCV) is a subtype of neovascular AMD with branching vascular network and polypoidal choroidal vascular lesions that can cause sub-retinal hemorrhage and may be less responsive to some anti-VEGF monotherapies.
    Epidemiology notePCV is more common in Asian populations and can be under-diagnosed in Western populations.
    Therapeutic relevanceTreatment options include anti-VEGF monotherapy or combination with PDT; some trials show meaningful VA gains and polyp regression with aflibercept.
    Polypoidal choroidal vasculopathy (PCV) — additional definition snippet
    Additional PCV notePCV lesions may demonstrate polyp regression on ICGA and anatomic improvement on OCT after aflibercept monotherapy in prospective studies.
    Clinical trial resultExample: 62% polyp disappearance on ICGA after 5 aflibercept injections in a 28-week prospective study.
    ImplicationDocument lesion characterization (ICGA/OCT) and response when considering therapy for PCV per policy documentation guidance.
    Retinopathy of prematurity (ROP) — definition and clinical note
    ROP definitionRetinopathy of prematurity (ROP) is a vasoproliferative retinal disorder of premature infants; anti-VEGF agents can produce regression but long-term systemic and neurodevelopmental effects are uncertain.
    Treatment considerationsAnti-VEGF agents are effective for Type 1 ROP and may be advantageous in zone I/AP-ROP, but recurrence rates are higher and extended vigilant follow-up is required.
    Safety cautionSystemic VEGF suppression has been detected for at least 8–12 weeks after intravitreal bevacizumab; use is advised judiciously given unknown long-term effects.
    BCVA / ETDRS letters — endpoint definition
    BCVA / ETDRS letters (endpoint)BCVA measured in ETDRS letter score is used as a primary efficacy endpoint in trials (e.g., mean change in letters at specified weeks).
    Reporting examplesTrials report mean letter gains (e.g., +13 letters in PCV study; +10.9 letters with aflibercept monthly in VIEW).
    Use for authorizationBCVA change at trial-specified timepoints may be cited to support medical necessity and reauthorization documentation.
    CMT / CMT decrease — central macular thickness definition
    CMT / CFT definitionCentral macular thickness (CMT) or central foveal thickness (CFT) is measured by OCT and used as an anatomic outcome to assess edema and response to therapy.
    Example useCFT ≥300 μm was an inclusion threshold in a switch study of RVO-related CME; mean CFT decreases are reported as treatment response metrics.
    Measurement roleOCT-measured CMT/CFT guides retreatment decisions and provides objective anatomic documentation for authorizations.
    Active choroidal neovascularization (CNV) — definition and diagnostic tests
    Active CNV definitionActive choroidal neovascularization (CNV) is presence of subretinal neovascular process causing visual loss, demonstrated by fluorescein angiography or OCT, and is an indication for intravitreal anti-VEGF therapy in many conditions.
    Diagnostic testsFluorescein angiography (FA) and optical coherence tomography (OCT) are used to document active CNV and guide treatment decisions and coverage for rare CNV causes.
    Coverage implicationFor rare CNV causes, intravitreal bevacizumab may be indicated when active CNV is documented by FA or OCT per policy guidance.
    CATT study finding — comparative-effectiveness finding summary
    CATT study findingCATT randomized trial found equivalent visual acuity outcomes at 1 year for bevacizumab versus ranibizumab when administered on the same schedule, but a higher proportion of serious systemic adverse events was reported with bevacizumab (24.1% vs 19.0%).
    ImplicationComparative-effectiveness data may inform step therapy and prescriber selection decisions; monitor for differing safety signals between agents.
    Documentation useTrial evidence like CATT can support use of bevacizumab as an effective lower-cost alternative when selection criteria are met.
    Type 1 ROP — definition and treatment threshold
    Type 1 ROP definitionType 1 ROP meets treatment thresholds where anti-VEGF agents or laser photocoagulation are recommended; anti-VEGF can induce regression but requires extended follow-up due to incomplete vascularization and higher recurrence risk.
    Treatment considerationsAnti-VEGF advantages include structural benefits in some Zone I or aggressive posterior ROP cases; systemic VEGF suppression and long-term effects remain uncertain.
    Interval/noteWhen using aflibercept for ROP, minimum interval between doses in same eye is at least 10 days (Eylea dosing guidance).
    Brolucizumab-dbll (Beovu) — product definition
    Brolucizumab (Beovu) definitionBrolucizumab-dbll (Beovu) is a recombinant human VEGF inhibitor approved for neovascular (wet) AMD and diabetic macular edema that binds VEGF-A isoforms to suppress endothelial proliferation and vascular permeability.
    Safety noteBeovu carries warnings for intraocular inflammation, retinal vasculitis/vascular occlusion, and other injection-related risks per label.
    Dosing summaryRecommended dose: 6 mg via intravitreal injection with initial loading then maintenance every 8–12 weeks for nAMD; DME regimens differ (see dosing section).
    Faricimab-svoa (Vabysmo) — product definition
    Faricimab (Vabysmo) definitionFaricimab-svoa (Vabysmo) is a bispecific antibody that inhibits VEGF-A and angiopoietin-2, indicated for nAMD, DME, and macular edema following RVO, with potential for extended dosing up to every 16 weeks based on disease activity.
    Efficacy evidenceTENAYA/LUCERNE and YOSEMITE/RHINE trials demonstrated non-inferiority to aflibercept with potential extended durability (up to q16w) in many patients.
    Contraindications/warningsContraindicated in ocular/periocular infection, active intraocular inflammation, and hypersensitivity; monitor for endophthalmitis, IOP changes, and thromboembolic events.
    Pegaptanib (Macugen) — product discontinued note
    Pegaptanib (Macugen) notePegaptanib (Macugen) is a selective VEGF antagonist previously FDA-approved for neovascular AMD but has been discontinued and is no longer available in the U.S.
    Availability implicationMentioned for historical context; not an available treatment option for current coverage decisions.
    Policy stancePolicy notes Macugen is discontinued and unavailable in the U.S.
    Ranibizumab (Lucentis and biosimilars) — product definition
    Ranibizumab (Lucentis & biosimilars)Ranibizumab is a recombinant monoclonal antibody fragment that binds VEGF‑A and is administered by intravitreal injection (Lucentis, Cimerli, Byooviz) for multiple retinal vascular/neovascular conditions.
    Common dosingLucentis 0.5 mg monthly for nAMD and RVO; 0.3 mg monthly for DME/DR; biosimilars use similar dosing per labeling.
    Safety/contraindicationsContraindicated in ocular/periocular infection and hypersensitivity; carries warnings for endophthalmitis and retinal detachment post-injection.
    Faricimab (Vabysmo) — product definition (duplicate)
    Faricimab (Vabysmo) summaryFaricimab is a bispecific antibody approved for DME and macular edema following RVO and nAMD; trials showed vision gains comparable to aflibercept with adjustable dosing intervals up to q16w in many patients.
    Durability potentialTrials demonstrated potential to extend treatment intervals (up to every 16 weeks) while maintaining efficacy in selected patients.
    IndicationsApproved indications include DME, nAMD, and macular edema following RVO per FDA labeling.

    Policy Revision History

    2026-07-30policy_reviewLatest

    Policy last reviewed; aflibercept (Eylea and listed biosimilars) dosing and indications described including PULSAR trial results for Eylea HD (noninferiority to 2 mg q8).